OCGN - DD - June 2021 | Ocugen - OCGN

OCGN - Ocugen 23:02 PM - May 31 2021

by: Maverick

Overview

Current price: 8.73
O/S: 200M
Float: 192M
URL: ocugen.com
What they do: Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.

Upcoming catalysts

Other notes

IP unclear downtoearth.org.in/blog/health...
Bharat Biotech sold Ocugen exclusive rights to COVAXIN in the US in February 2021
Ocugen will receive 45% of the profits from Covaxin's U.S. sales.
Covaxin was developed in partnership between the Government of India and Bharat Biotech. The vaccine was granted approval for emergency use by the Indian authorities in early January. Several million people have received the vaccine in India.
In the call with analysts, Musunuri said Covaxin is different from the other Covid-19 vaccine options already approved for emergency use in the U.S.. The other vaccines, he said, rely on new mRNA, or adenovirus technology, while Covaxin uses a traditional approach of using an inactivated vaccine.

They cancelled the EUA and went BLA on June 10. I was lucky because I got impatient and sold on June 7.

ocugen.gcs-web.com/news-releas...